Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: AARTIDRUGS

Aarti Drugs

Results filed 3 November 2026 · Market cap ₹4,631 crore · PE 20.1

GrowthGuidance maintainedTranscript read

Revenue
+26.6%
on a year ago
EBITDA
+60.6%
on a year ago
Profit to shareholders
+83.2%
on a year ago
EBITDA margin
16.4%
+2.4 pts on last quarter

Aarti Drugs reported consolidated revenue growth of 27% YoY to Rs. 828.8 crore in Q2 FY27, with EBITDA expanding 63% to Rs. 137.9 crore and margins reaching 16.6%. Performance was heavily supported by 17-18% price realization gains and 58% growth in formulations, offsetting modest API volume growth of 5%. Despite strong accounting profit growth, H1 FY27 operating cash flow declined to Rs. 65.7 crore due to working capital absorption in receivables and inventory.

Aarti Drugs Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue826703+17.6%653+26.6%
Operating profit (EBIT)11679.74+45.9%68.02+71.1%
Operating margin14.1%11.3%+274 bps10.4%+366 bps
Other income2.550.81+214.8%0.09+2733.3%
Exceptional items0−2.09–0–
Profit before exceptional items and tax10971.33+53.2%60.41+80.9%
Profit to shareholders82.9450.17+65.3%45.28+83.2%
Earnings per share (₹)9.075.49+65.2%4.95+83.2%

Source: Aarti Drugs Limited’s filing to NSE, 3 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

What stood out

  • Record quarterly financial performance with highest-ever quarterly EBITDA of Rs. 138 crore and multi-year peak margin of 16.6%.
    SourceTotal consolidated revenue was at Rs. 829 crores... EBITDA grew 63% to Rs. 138 crores, the highest quarterly EBITDA we have ever reported, with our EBITDA margin for the quarter reaching 16.6%, up 370 basis points year-on-year basis and the highest we have achieved in nearly 6 years (Transcript p. 2, Adhish Patil).
  • Growth driven predominantly by price realizations (+17% to 18%) rather than volume expansion (+5%).
    SourceSo, for the API business on a YoY basis, we saw a price growth of almost around 17 to 18%... And the overall volume growth was around 5% for both API and spec chem put together (Transcript p. 5, Adhish Patil).
  • Formulations subsidiary (Pinnacle Life Science) delivered sharp growth with 28% EBITDA margin on strong exports.
    SourceOur formulations business also had an excellent quarter, growing 58% from Rs. 82 crores in Q2 FY26 to Rs. 130 crores in Q2 FY27, led by exports which rose 73% year-on-year... this particular quarter, we made exceptional EBITDA margins of roughly around 28% due to good export orders (Transcript p. 3, 6, Adhish Patil).
  • Leadership transition as founder Prakash M. Patil stepped down and Adhish Patil took over as Managing Director.
    SourceStarting October 1st 2026, Mr. Prakash M. Patil retired as Chairman, Managing Director and CEO... With Mr. Rashesh Gogri taking over as Chairman, and as I take charge as Managing Director (Investor Presentation p. 11, Investor Release p. 3).

Guidance

MetricGuidancePeriod
Consolidated EBITDA Margin
SourceYes. So, the overall company margins, we do feel that 15% should be sustainable, though for this particular quarter, we have achieved EBITDA margins of around 16.6% (Transcript p. 5, 6, Adhish Patil).
Sustainable upwards of 15% (steady state), factoring in normalization of formulation EBITDA margins to 20% and standalone margins at 14%.Medium to long term
Standalone API Volume Growth
SourceSo, once they start believing that this is a new normal, then the volume growth and the demand should start to come in. And in that case, we can expect high single digit volume growth. But as of now, we are not that sure. So, we will assume somewhere between 5% to 10% volume growth (Transcript p. 7, Adhish Patil).
5% to 10% volume growth expected for the second half of FY27.H2 FY27
Formulation Revenue Target
SourceRight. So, yes, that is the belief that we think that we can achieve the Rs.1,000 crore landmark earlier than what we have published (Transcript p. 8, Vishwa Savla).
Achieving Rs. 1,000 crore revenue milestone earlier than originally published.Medium term
Oncology Revenue Share in Formulations
SourceSo, contribution to revenue from the oncology at FY30 level. We estimate it to be between late 30s to early 40s percentage maybe (Transcript p. 10, Vishwa Savla).
Late 30s to early 40s percentage of formulation revenue.FY30

Tailwinds

  • Favorable API pricing and realizations supported by geopolitical events in West Asia.
    SourceDevelopments in West Asia kept API prices firm across the industry while customers increasingly prioritized reliable and uninterrupted supply of APIs. Aarti Drugs was well-placed to benefit from this, delivering a 16% improvement in realizations year-on-year (Transcript p. 2, Adhish Patil).
  • Operational benefits from backward integration at Sayakha Methylamines facility.
    SourceDuring the quarter, the plant operated at around 72% utilization and captive consumption of our antidiabetic portfolio rose to around 85%. These gains in product mix, backward integration and cost efficiency are structural (Transcript p. 3, Adhish Patil).
  • Surge in formulation export sales across newly registered territories.
    SourceFormulations business recorded revenue of Rs. 130 crores in Q2 FY27 compared to Rs. 83 crores in Q2 FY26, up 58% YoY, led by exports which rose 73% year-on-year and contributed 74% to formulation revenue (Transcript p. 3, 4, Adhish Patil).

Headwinds

  • Low volume growth due to customer destocking amid higher market prices.
    SourceWhen we started with the year, we were targeting roughly around 10% odd volume growth at the company level. Though first half, we just were able to achieve 3% and 5% respectively volume growth in the standalone segment... purchasing people at the formulation side, they try to refrain overstocking (Transcript p. 7, Adhish Patil).
  • Standalone export sales contraction.
    SourceDomestic revenue grew 43% YoY while export revenue declined 5% YoY in the standalone business for Q2 FY27 (Investor Release p. 3, Investor Presentation p. 8).
  • Substantial working capital buildup impairing H1 FY27 operating cash flow.
    SourceWorking capital changes stood at -Rs. 140.3 crores in H1 FY27 (vs -Rs. 9.0 crores in H1 FY26), pulling cash generated from operations down to Rs. 94.0 crores from Rs. 152.1 crores and net operating cash flow to Rs. 65.7 crores vs Rs. 152.4 crores (Investor Presentation p. 10).
  • Delays in the imposition of anti-dumping duty on salicylic acid.
    SourceAdditionally, nine months data we have to submit. So now, after the result is published, we will be submitting the anti-dumping duty now... they intimated that will initiate before the year-end, December... then they will take another three to six-month period (Transcript p. 8-9, Harshit Shah).

New businesses and products

capacity expansion · Underway

Tarapur USFDA Multipurpose Block Expansion

Expected benefit
Revenue potential between Rs. 180 to 200 crores on a full-scale basis; more than doubles capacity and adds flexibility for regulated markets.
Risks
Gestation timeline and regulatory approvals for new blocks.
Timeline
18 to 20 months with commercial production targeted towards end of FY29.
Investment
Not explicitly quantified (part of ongoing capex).
SourceWe are also expanding our USFDA approved block at Tarapur by building an adjacent block which will more than double its capacity... three new multipurpose plants... commercial production targeted towards the end of FY29... revenue potential anywhere between Rs. 180 to 200 crores on a full-scale basis (Transcript p. 3, 9, Adhish Patil).

capacity expansion · Underway

Sarigam Metformin Capacity Expansion and Dedicated USFDA Block

Expected benefit
Capacity expansion to 1,700 TPM (scaling to 2,000-2,200 TPM) and entering US regulated metformin market.
Risks
Regulatory approval of USFDA DMF filings.
Timeline
Early FY28 for 1,700 TPM; dedicated USFDA block by end of FY28.
Investment
Not explicitly quantified.
SourceAt Sarigam, we are increasing our metformin capacity from 1400 tons per month to 1700 tons per month with commercialization planned in early FY28. Alongside this, we are adding a dedicated 500 tonnes per month USFDA compliant block by the end of FY28. And our USFDA DMFs for metformin is under preparation (Transcript p. 3, Adhish Patil; Investor Presentation p. 33).

capacity expansion · Underway

Baddi Formulations Brownfield Expansion

Expected benefit
Nearly doubles current oral solid dosage capacity to support long-term formulations revenue target of Rs. 1,000 crores and access US/EU markets.
Risks
Regulatory clearance and audit timelines.
Timeline
Completion expected by mid of next year.
Investment
Part of Rs. 200 crore formulation/oncology pipeline investments over past 24 months.
SourceAt our facility in Baddi in Himachal Pradesh, we are executing a brownfield expansion which involves utilizing an adjacent plot to nearly double the current oral solid dosage manufacturing capacity... by the mid of next year should double our capacities (Transcript p. 3, 8, Adhish Patil and Vishwa Savla; Investor Presentation p. 32).

new product · Initiated commercial launch

US Oncology Formulations Launch and Pipeline

Expected benefit
Higher gross margin profile; targeted to contribute late 30s to early 40s percent of formulation revenue by FY30.
Risks
Pricing pressure and speed of ANDA approvals.
Timeline
Revenue ramp up over next 3-6 months; 4-5 filings planned in rolling 12 months; target maturity by FY30.
Investment
Rs. 200 crore invested over last 24 months solely for oncology development and pipeline.
SourceWe have a small contribution in this quarter from the US oncology product... expect that in the coming three to six months, the US revenue would increase... contribution to revenue from the oncology at FY30 level. We estimate it to be between late 30s to early 40s percentage (Transcript p. 8, 10, Vishwa Savla; Investor Presentation p. 32).

Things to check

  • Significant operating cash flow compression in H1 FY27 due to working capital expansion.
    SourceOperating cash flow after tax dropped 57% YoY to Rs. 65.7 crores in H1 FY27 from Rs. 152.4 crores in H1 FY26, driven by a negative working capital swing of Rs. 140.3 crores as inventories rose to Rs. 603.1 crores and receivables reached Rs. 905.0 crores (Investor Presentation p. 9, 10).
  • Topline growth largely driven by conflict-led pricing rather than structural volume demand.
    SourceAdhish Patil noted API price growth was 17-18% due to West Asia geopolitical disruptions and crude/gas linkage, while volume growth was only 5% as buyers deferred purchases (Transcript p. 2, 5, 7).

How the call went

The call was substantive, with transparent disclosures around price-volume breakdowns and capex timelines, although management avoided quantifying exact inventory-driven windfall margin contributions.

Specific or vague
High clarity on volume vs price split (17-18% realization vs 5% volume), segmental EBITDA margins (formulation ~28%, standalone >14%), plant utilization (Sayakha at 72%, antidiabetic captive at 85%), and order book visibility (4 months in formulation exports, 2.5-3 months in API exports, <1 month in domestic).
Candour
Management acknowledged that the volume target of 10% was missed in H1 (achieving 3% and 5%) due to pricing resistance and customer wait-and-see behavior, and openly framed Q2's 16.6% EBITDA margin as higher than steady-state sustainable levels (guided at ~15%).
The hard questions
Analysts directly challenged the sustainability of the 28% formulation EBITDA margin, the degree to which margins benefited from transient geopolitical price increases, and the timeline delays on salicylic acid anti-dumping duties.

What analysts pressed on

  • Longevity of peak realization gains driven by West Asia conflict and crude pricing.
  • Durability of exceptionally high (~28%) formulation EBITDA margins beyond the current 4-month order book.
  • Subdued underlying volume growth in the core API business.
  • Persistent dumping of Chinese salicylic acid and protracted timeline for anti-dumping duty implementation.

Answers that sidestepped

  • Adhish Patil refrained from quantifying exact gross margin or inventory gain split from raw materials purchased before peak prices, citing portfolio complexity.

Numbers against the story

Management celebrated record revenue and a near 6-year peak EBITDA margin of 16.6%, framing the gains as structural improvements from backward integration at Sayakha. However, the operational data shows that topline growth was predominantly propelled by 17-18% pricing spikes caused by West Asia disruptions, while volume growth remained low at 5% (against an initial 10% annual budget). Furthermore, despite PAT jumping 83% YoY in Q2, H1 cash flow from operations plunged from Rs. 152.4 crore to Rs. 65.7 crore due to a severe working capital drag of Rs. 140.3 crore.

Sources

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.